Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats

Epilepsia

Volumn 51, Issue 3, 2010, Pages 362-370

  Van Vliet, Erwin A ^a,b   Edelbroek, Peter M ^a   Gorter, Jan A ^a,b  

^a STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Antiepileptic drug; Pharmacoresistance; Status epilepticus; Temporal lobe epilepsy; Tolerance

Indexed keywords

ETIRACETAM; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERANCE; ELECTROENCEPHALOGRAPHY; EPILEPTIC DISCHARGE; EPILEPTIC STATE; GAS CHROMATOGRAPHY; MALE; MONOTHERAPY; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; SEIZURE;

ANIMALS; ANTICONVULSANTS; DENTATE GYRUS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG TOLERANCE; ELECTRIC STIMULATION; ELECTROENCEPHALOGRAPHY; EPILEPSY; EPILEPSY, TEMPORAL LOBE; HUMANS; MALE; PIRACETAM; RATS; RATS, SPRAGUE-DAWLEY; STATUS EPILEPTICUS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 77749239703     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2009.02261.x     Document Type: Article

References (38)

1. Baltes S, Fedrowitz M, Tortos CL, Potschka H, Loscher W. (2007) Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther 320:331-343.
2. Beck H. (2007) Plasticity of antiepileptic drug targets. Epilepsia 48(suppl 1):14-18.
3. Brandt C, Bethmann K, Gastens AM, Loscher W. (2006) The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 24:202-211.
4. Brodie MJ, Mohanraj R. (2003) Pharmacological outcomes in newly diagnosed epilepsy. Epilepsia 44:84.
5. Bruni J, Albright P. (1983) Valproic acid therapy for complex partial seizures. Its efficacy and toxic effects. Arch Neurol 40:135-137.
6. De Smedt T, Raedt R, Vonck K, Boon P. (2007) Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev 13:57-78.
7. Feuerstein J, Revol M, Roger J, Sallou C, Truelle JL, Vercelletto P, Weber M. (1983) [Monotherapy with sodium valproate in generalized primary epilepsy. 2d phase: study of long-term efficacy and tolerance]. Sem Hop 59:1263-1274.
8. Friedman D, French JA. (2006) Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures. Neurology 66:590-591.
9. Gorter JA, van Vliet EA, Aronica E, Lopes daSilva FH. (2001) Progression of spontaneous seizures after status epilepticus is associated with mossy fibre sprouting and extensive bilateral loss of hilar parvalbumin and somatostatin-immunoreactive neurons. Eur J Neurosci 13:657-669.
10. Jakutiene E, Grikiniene J, Vaitkevicius A, Tschaika M, Didziapetriene J, Stakisaitis D. (2007) Sodium valproate stimulates potassium and chloride urinary excretion in rats: gender differences. BMC Pharmacol 7:9.
11. Johannessen CU. (2000) Mechanisms of action of valproate: a commentary. Neurochem Int 37:103-110.
12. Klotz U, Schweizer C. (1980) Valproic acid in childhood epilepsy: anticonvulsive efficacy in relation to its plasma levels. Int J Clin Pharmacol Ther Toxicol 18:461-465.
13. Kwan P, Brodie MJ. (2000) Early identification of refractory epilepsy. N Engl J Med 342:314-319.
14. Kwan P, Sills GJ, Brodie MJ. (2001) The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 90:21-34.
15. Leite JP, Cavalheiro EA. (1995) Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res 20:93-104.
16. Loscher W, Nau H. (1983) Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. J Pharmacol Exp Ther 226:845-854.
17. Loscher W. (1986) Development of tolerance to the anticonvulsant effect of GABAmimetic drugs in genetically epilepsy-prone gerbils. Pharmacol Biochem Behav 24:1007-1013.
18. Loscher W, Schmidt D. (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations Epilepsy Res 2:145-181.
19. Loscher W, Fisher JE, Nau H, Honack D. (1989) Valproic acid in amygdala-kindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment. J Pharmacol Exp Ther 250:1067-1078.
20. Loscher W, Schmidt D. (2004) New horizons in the development of antiepileptic drugs: the search for new targets. Epilepsy Res 60:77-150.
21. Loscher W, Schmidt D. (2006) Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 47:1253-1284.
22. Loscher W. (2007) The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy. Epilepsia 48:1245-1258.
23. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101:9861-9866.
24. Mana MJ, Kim CK, Pinel JP. (1992a) Tolerance to the anticonvulsant effects of carbamazepine, diazepam, and sodium valproate in kindled rats. Pharmacol Biochem Behav 41:109-113.
25. Mana MJ, Kim CK, Pinel JP, Jones CH. (1992b) Contingent tolerance to the anticonvulsant effects of carbamazepine, diazepam, and sodium valproate in kindled rats. Pharmacol Biochem Behav 41:121-126.
26. Mohanraj R, Brodie MJ. (2006) Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 13:277-282.
27. Neels HM, Sierens AC, Naelaerts K, Scharpe SL, Hatfield GM, Lambert WE. (2004) Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 42:1228-1255.
28. Nissinen J, Pitkanen A. (2007) Effect of antiepileptic drugs on spontaneous seizures in epileptic rats. Epilepsy Res 73:181-191.
29. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. (2008) Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49:1239-1276.
30. Regesta G, Tanganelli P. (1999) Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 34:109-122.
31. Rogawski MA, Loscher W. (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553-564.
32. Schmidt D, Loscher W. (2005) Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 46:858-877.
33. Sisodiya SM. (2003) Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 16:197-201.
34. Van Vliet EA, Aronica E, Tolner EA, Lopes daSilva FH, Gorter JA. (2004) Progression of temporal lobe epilepsy in the rat is associated with immunocytochemical changes in inhibitory interneurons in specific regions of the hippocampal formation. Exp Neurol 187:367-379.
35. Van Vliet EA, Van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, Marchi N, Vezzani A, Gorter JA. (2006) Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 47:672-680.
36. Van Vliet EA, van Schaik R, Edelbroek PM, Lopes daSilva FH, Wadman WJ, Gorter JA. (2008) Development of tolerance to levetiracetam in rats with chronic epilepsy. Epilepsia 49:1151-1159.
37. Vreugdenhil M, van Veelen CW, van Rijen PC, Lopes daSilva FH, Wadman WJ. (1998) Effect of valproic acid on sodium currents in cortical neurons from patients with pharmaco-resistant temporal lobe epilepsy. Epilepsy Res 32:309-320.
38. Wahle H, Frey HH. (1990) Development of tolerance to the anticonvulsant effect of valproate but not to ethosuximide in a rat model of absence epilepsy. Eur J Pharmacol 181:1-8.